Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen

齐欢畅

Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen
Oct 31, 2018 at 7:30 AM EDT
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 31, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson
PDF Version
PASADENA, Calif.--(BUSINESS WIRE)--Oct. 31, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the stock purchase agreement between Arrowhead and Johnson & Johnson Innovation – JJDC, Inc., (JJDC) have closed, following termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

齐欢畅

与詹森箭头制药宣布关闭的协议
2018年10月31日,在早上7:30
加州帕萨迪纳市——(业务线)——10月。 31日,2018年,箭头制药有限公司(纳斯达克:ARWR)今天宣布,许可协议和研究之间的协作和选择权协议箭头和詹森制药,Inc .,约翰逊詹森制药公司的一部分
PDF版本
加州帕萨迪纳市。——(业务线)——10月。 31日,2018年,箭头制药公司。(纳斯达克:ARWR)今天宣布 协议许可协议和科研协作和选项 之间的箭头和詹森制药有限公司,詹森的一部分 制药公司的强生公司,和股票购买 协议之间的箭头和强生公司创新-JJDC, 公司。(JJDC)已经关闭,等待期后终止 下Hart-Scott Rodino垄断Act of 1976),改进 修改。

关于箭头制药